These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The dopamine transporter role in psychiatric phenotypes. Salatino-Oliveira A; Rohde LA; Hutz MH Am J Med Genet B Neuropsychiatr Genet; 2018 Mar; 177(2):211-231. PubMed ID: 28766921 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of dopamine transporter knockout mice as an animal model of AD/HD]. Kasahara Y; Kubo Y; Sora I Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):185-9. PubMed ID: 25069256 [TBL] [Abstract][Full Text] [Related]
6. Strengths and limitations of genetic models of ADHD. Gainetdinov RR Atten Defic Hyperact Disord; 2010 Mar; 2(1):21-30. PubMed ID: 21432587 [TBL] [Abstract][Full Text] [Related]
7. Towards trans-diagnostic mechanisms in psychiatry: neurobehavioral profile of rats with a loss-of-function point mutation in the dopamine transporter gene. Vengeliene V; Bespalov A; Roßmanith M; Horschitz S; Berger S; Relo AL; Noori HR; Schneider P; Enkel T; Bartsch D; Schneider M; Behl B; Hansson AC; Schloss P; Spanagel R Dis Model Mech; 2017 Apr; 10(4):451-461. PubMed ID: 28167616 [TBL] [Abstract][Full Text] [Related]
8. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Zhuang X; Oosting RS; Jones SR; Gainetdinov RR; Miller GW; Caron MG; Hen R Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1982-7. PubMed ID: 11172062 [TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder. Mereu M; Contarini G; Buonaguro EF; Latte G; Managò F; Iasevoli F; de Bartolomeis A; Papaleo F Neuropharmacology; 2017 Jul; 121():179-194. PubMed ID: 28454982 [TBL] [Abstract][Full Text] [Related]
10. [Neuronal development of the hyperdopaminergic animal model]. Kasahara Y; Arime Y; Kubo Y; Fukui A; Sora I Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):195-9. PubMed ID: 22256607 [TBL] [Abstract][Full Text] [Related]
11. [Behavioral and pharmacological characteristics of mice lacking the dopamine transporter]. Biala G Postepy Hig Med Dosw (Online); 2004; 58():560-4. PubMed ID: 15765018 [TBL] [Abstract][Full Text] [Related]
12. A short review on the relation between the dopamine transporter 10/10-repeat allele and ADHD: implications for HIV infection. Koutsilieri E; Riederer P; du Plessis S; Scheller C Atten Defic Hyperact Disord; 2014 Sep; 6(3):203-9. PubMed ID: 24696011 [TBL] [Abstract][Full Text] [Related]
13. Rats overexpressing the dopamine transporter display behavioral and neurobiological abnormalities with relevance to repetitive disorders. Hadar R; Edemann-Callesen H; Reinel C; Wieske F; Voget M; Popova E; Sohr R; Avchalumov Y; Priller J; van Riesen C; Puls I; Bader M; Winter C Sci Rep; 2016 Dec; 6():39145. PubMed ID: 27974817 [TBL] [Abstract][Full Text] [Related]
14. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. Sotnikova TD; Beaulieu JM; Gainetdinov RR; Caron MG CNS Neurol Disord Drug Targets; 2006 Feb; 5(1):45-56. PubMed ID: 16613553 [TBL] [Abstract][Full Text] [Related]
15. [The dopamine transporter: characterization and physiopathologic implications]. Thibaut F; Vaugeois JM; Petit M Encephale; 1995; 21(6):445-51. PubMed ID: 8674469 [TBL] [Abstract][Full Text] [Related]
16. A murine model of hyperdopaminergic state displays altered respiratory control. Vincent SG; Waddell AE; Caron MG; Walker JK; Fisher JT FASEB J; 2007 May; 21(7):1463-71. PubMed ID: 17255472 [TBL] [Abstract][Full Text] [Related]
17. Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout. Hall FS; Sora I; Hen R; Uhl GR PLoS One; 2014; 9(12):e115009. PubMed ID: 25514162 [TBL] [Abstract][Full Text] [Related]
18. Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans. Reckziegel P; Chen P; Caito S; Gubert P; Soares FA; Fachinetto R; Aschner M Arch Toxicol; 2016 Mar; 90(3):633-45. PubMed ID: 25579234 [TBL] [Abstract][Full Text] [Related]
19. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. van der Kooij MA; Glennon JC Neurosci Biobehav Rev; 2007; 31(4):597-618. PubMed ID: 17316796 [TBL] [Abstract][Full Text] [Related]
20. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]